4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Small Artery Remodelling (SmArteR)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2017,
Cardiovascular disease remains a major cause of morbidity and mortality in Europe. Small arteries form a key element in the pathogenesis. Thus, these vessels dictate local perfusion and blood pressure by adaptation of their caliber. Structural changes towards smaller caliber, small artery remodelling, cause hypertension and decreased organ perfusion, leading to acute events and chronic end organ d ...
Voir le projet
11
Participants partenaires
TERMINÉ
"The NGF system and its interplay with endocannabinoid signalling, from peripheral sensory terminals to the brain: new targets for the development of next generation drugs for neuropathic pain" (PAINCAGE)
Date du début: 1 avr. 2014, Date de fin: 31 mars 2017,
"So far, there are no effective treatments for neuropathic pain (NP), and current treatments suffer from serious unwanted side effects.The NGF ligand-receptor system has recently emerged as a novel target for NP of great therapeutic potential, a master regulator, controlling both neuropathic and inflammatory components. Besides being a multi-component system, it also modulates the endocannabinoid ...
Voir le projet
9
Participants partenaires
TERMINÉ
Targeting Receptors Of Jointly Assembled Ligand-Drug Constructs (TROJA)
Date du début: 1 avr. 2009, Date de fin: 31 mars 2014,
The TROJA proposal is an investigative bioengineering study of the exploitation of specific endocytic receptors for targeting small molecule drugs to specific cells in order to improve medical therapy. This is a new approach with scientific roots in the basic research on endocytic receptors and protein expression carried out in the laboratory of the applicant. The major line of the proposal concer ...
Voir le projet
1
Participant partenaire
TERMINÉ
Targeting macrophage CD163 for treatment of non-alcoholic steatohepatitis (NASH)
Date du début: 1 déc. 2012, Date de fin: 30 nov. 2013,
"Macrophages play a key role in inflammatory diseases. One of the goals of the TROJA ERC program has been to explore drug targeting via the haemoglobin scavenger receptor CD163, which has a high and exclusive expression in macrophages. We have now developed new biodegradable anti-CD163 antibody-drug conjugates by linking drugs directly to anti-CD163 antibody and by encapsulating drugs in liposome ...
Voir le projet